Oncopeptides Virtual Capital Markets Day

14.00 – 16.00 CET (8:00am-10am EST) November 30th, 2020

The Program

“Building a Fully Integrated Biotechnology Company”

  • Introduction and Strategy for Value Growth – Marty J Duvall, CEO Oncopeptides
  • Multiple Myeloma
    “Myeloma remains one of the largest unmet medical needs within hematology”
    o Assistant Professor Joshua Richter, MD. Icahn School of Medicine at Mount Sinai Hospital, New York
  • Relapsed refractory multiple myeloma and melflufen – clinical experience with melflufen – Panel discussion
    o Professor Paul Richardson, MD, Dana-Farber Cancer Institute, Boston
    o Associate Professor Maria-Victoria Mateos, MD, PhD, University Hospital, Salamanca
    Moderated by Klaas Bakker, MD, PhD, CMO Oncopeptides
  • The clinical development program for melflufen
    “Understanding how melflufen can help patients the most” – Jakob Lindberg, CSO Oncopeptides
  • Successfully making the drug available for patients in the US
    Overview of US launch of melflufen – Marty J Duvall, CEO Oncopeptides
  • Questions and Answers

 

The virtual CMD was webcasted live and recorded

To get to the webcast klick on the link: https://tv.streamfabriken.com/oncopeptides-cmd-2020.
The presentations from the capital markets day is uploaded below.